1. Home
  2. XGN vs CYBN Comparison

XGN vs CYBN Comparison

Compare XGN & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$7.01

Market Cap

253.9M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$6.67

Market Cap

298.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
CYBN
Founded
2002
2019
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.9M
298.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
XGN
CYBN
Price
$7.01
$6.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$13.67
$74.50
AVG Volume (30 Days)
307.0K
626.1K
Earning Date
11-04-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,599,000.00
N/A
Revenue This Year
$22.15
N/A
Revenue Next Year
$15.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.08
N/A
52 Week Low
$2.67
$4.81
52 Week High
$12.23
$10.73

Technical Indicators

Market Signals
Indicator
XGN
CYBN
Relative Strength Index (RSI) 29.11 60.24
Support Level $7.01 $5.70
Resistance Level $7.29 $6.20
Average True Range (ATR) 0.32 0.36
MACD 0.07 0.10
Stochastic Oscillator 15.42 75.00

Price Performance

Historical Comparison
XGN
CYBN

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: